A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
Clinical trial NCT06275620 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06275620
- Sponsor
- Beacon Therapeutics
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-14
- Primary completion
- 2025-11-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.